The global multiplex assays market size is expected to reach USD 5.57 billion by 2030, according to a new study by Polaris Market Research. The report “Multiplex Assays Market Share, Size, Trends, Industry Analysis Report, By Technology; By Type (Protein Multiplex Assays, Nucleic Acid Multiplex Assays, Cell-Based Multiplex Assays); By Application, By End-User; By Region; Segment Forecast, 2022 - 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The key factors driving the market's growth include adopting multiplex assays across various verticals such as health services and others. Due to the growing use of customized treatment and benefits over standard tests, the market is expected to rise rapidly. Medical science, which has gained popularity in recent years, strives to provide individual patients with tailored therapies based on the molecular foundation of their disease.
Based on the type, the nucleic acid segment accounted for the leading share in the industry in 2021. This is due to the rising use of nucleic acids, ease of configuration to detect practically any target, low sample volume requirements, and level of automation to be achieved. A rise in the use of molecular diagnostic tests developed to diagnose diseases, such as human genetic markers, such as cancer, and genetic markers for disease predisposition also contributes to the economic development of the nucleic acid-based segment.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/multiplex-assays-market/request-for-sample
Market players such as Luminex Corporation, Enzo Life Sciences, Inc., Promega Corporation, Meso Scale Diagnostics, Quanterix, Thermo Fisher Scientific Inc., Qiagen N.V., Illumina, Inc, Shimadzu Biotech, Abcam plc, Bio-Rad Laboratories, Inc., Becton Dickinson and Company, Randox Laboratories, Merck KGaA, Agilent Technologies, Inc., Olink, DiaSorin S.p.A., Antigenix America, Inc., Siemens Healthineers, PerkinElmer, Inc., Boster Biological Technology, Seegene, and Cayman Chemical Company are some key players operating in the global market.
In August 2021, The BD COR System, a new automated diagnostic system from Becton, Dickinson, and Company, was released. In centralized laboratories across the U.S., the system uses robots and sample management software algorithms for genetic disease testing. Thus, the development of new technologies by major players and adoption of them across various laboratories is boosting the market growth during the forecast period.
Polaris Market Research has segmented the multiplex assays market report based on type, technology, application, end-user, and region:
Multiplex assays, Type Outlook (Revenue - USD Billion, 2018 - 2030)
Multiplex assays, Technology Outlook (Revenue - USD Billion, 2018 - 2030)
Multiplex assays, Application Outlook (Revenue - USD Billion, 2018 - 2030)
Multiplex assays, End-User Outlook (Revenue - USD Billion, 2018 - 2030)
Multiplex assays, Regional Outlook (Revenue - USD Billion, 2018 - 2030)